BTIG Reiterates Buy on Vaxcyte, Maintains $89 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.1%

Neg 0% Neu 89.1% Pos 0%

BTIG analyst Thomas Shrader reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $89 price target.

Comments

No comments yet. Be the first!